Literature DB >> 1526084

Acetylation polymorphism of caffeine in a Japanese population.

M Hashiguchi1, A Ebihara.   

Abstract

The frequency distribution of N-acetylation of caffeine was determined in 140 unrelated healthy Japanese subjects by measuring the amount of two main metabolites of caffeine, 5-acetylamino-6-formyl-amino-3-methyluracil (AFMU) and 1-methylxanthine (1X), in urine after an oral dose of caffeine. N-Acetylation capacity for caffeine appeared to be polymorphic: 15 subjects (10.7%) were phenotyped as slow acetylators, whereas 125 subjects (89.3%) were phenotyped as rapid ones. The urinary molar excretion ratio of AFMU (AFMU/1X) in 2 hours-urine samples ranged from 0.03 (slow acetylators) to 2.66 (rapid acetylators). The frequency of slow acetylators in this study was similar to that reported previously for the isoniazid and dapsone polymorphism in Japanese populations.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1526084     DOI: 10.1038/clpt.1992.141

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  3 in total

1.  Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes.

Authors:  Etienne Patin; Luis B Barreiro; Pardis C Sabeti; Frédéric Austerlitz; Francesca Luca; Antti Sajantila; Doron M Behar; Ornella Semino; Anavaj Sakuntabhai; Nicole Guiso; Brigitte Gicquel; Ken McElreavey; Rosalind M Harding; Evelyne Heyer; Lluis Quintana-Murci
Journal:  Am J Hum Genet       Date:  2006-01-13       Impact factor: 11.025

2.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

Authors:  I Cascorbi; N Drakoulis; J Brockmöller; A Maurer; K Sperling; I Roots
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

3.  Whole blood concentrations of mefloquine enantiomers in healthy Thai volunteers.

Authors:  C Martin; F Gimenez; K N Bangchang; J Karbwang; I W Wainer; R Farinotti
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.